Remsima (infliximab): New IV formulation (100 mg and 350 mg concentrate for solution for infusion) contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance
17/02/2026
Medicines for human use
Direct healthcare professional communication (DHPC)
Important Safety Information from Celltrion Healthcare Ireland Ltd regarding Remsima (infliximab): New IV formulation (100 mg and 350 mg concentrate for solution for infusion) contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance